Michael Williams, MD
Endocrinology, Diabetes & Metabolism · Asheville, NCNPI 1972716462
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Amgen at 38.4% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NC, where the typical reported total is $1,143.
Across 13 payments — averaging $24.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$123
- Cequr Corporation$94
- Insulet Corporation$60
- Dexcom, Inc.$22
- BETA Bionics, Inc.$20
Across 1 payment — averaging $24,328 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$24K
What the payments were for
- Food & beverage$319100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 5 | $123 |
| Cequr Corporation | 3 | $94 |
| Insulet Corporation | 3 | $60 |
| Dexcom, Inc. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $20 |
How this compares
$319 in reported general payments places this provider in the 30th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 495 | $567,098 |
| OzempicSemaglutide | 319 | $490,093 |
| KerendiaFinerenone | 345 | $418,493 |
| MounjaroTirzepatide | 246 | $400,413 |
| TrulicityDulaglutide | 171 | $253,335 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 140 | $190,224 |
| FarxigaDapagliflozin Propanediol | 116 | $138,057 |
| ProliaDenosumab | 58 | $101,228 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 67 | $97,296 |
| Novolog FlexpenInsulin Aspart | 163 | $70,010 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $65,812 |
| Tresiba Flextouch U-100Insulin Degludec | 98 | $64,825 |
| InvokanaCanagliflozin | 71 | $63,894 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 52 | $63,183 |
| SynjardyEmpagliflozin/Metformin Hcl | 48 | $62,537 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $123 | $101,22858 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Asheville
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- Lauren BernsteinAsheville$307K
- Stephen WeinribAsheville$11K
- Hilary ThomasAsheville$10K
- Mark WarrenGreenville$915K
- Thomas OconnellBurlington$805K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.